Alectinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1425 publications

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: June 23, 2026

Inflammatory Myofibroblastic Tumor: A Case Report of Neoadjuvant Alectinib and Summary of Single-Institution Molecular Data.

Inflammatory Myofibroblastic Tumor: A Case Report of Neoadjuvant Alectinib and Summary of Single-Institution Molecular Data.

Journal: JCO precision oncology
Published: June 08, 2026

Perioperative Molecular Testing in Non-small Cell Lung Cancer

Perioperative Molecular Testing in Non-small Cell Lung Cancer

Journal: Zentralblatt fur Chirurgie
Published: June 08, 2026

Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series.

Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series.

Journal: Tumori
Published: June 04, 2026

Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non-Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT).

Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non-Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT).

Journal: JCO global oncology
Published: June 04, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; alectinib for solid tumors.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; alectinib for solid tumors.

Journal: International journal of clinical oncology
Published: June 02, 2026

Localized episcleral ALK-positive histiocytosis: a novel adult presentation confirmed by ALK gene rearrangement.

Localized episcleral ALK-positive histiocytosis: a novel adult presentation confirmed by ALK gene rearrangement.

Journal: Orbit (Amsterdam, Netherlands)
Published: May 19, 2026

Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing ALK Alteration Prolongs Treatment Duration.

Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing ALK Alteration Prolongs Treatment Duration.

Journal: JCO precision oncology
Published: May 18, 2026

First-Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK-Positive Non-Small Cell Lung Cancer with Brain Metastases: A Real-World Multicenter Study from Vietnam.

First-Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK-Positive Non-Small Cell Lung Cancer with Brain Metastases: A Real-World Multicenter Study from Vietnam.

Journal: Thoracic cancer
Published: May 13, 2026

Liver-originated selective autophagy of BTD by alectinib underlies concurrent hepatotoxicity and Dermatotoxicity.

Liver-originated selective autophagy of BTD by alectinib underlies concurrent hepatotoxicity and Dermatotoxicity.

Journal: Autophagy
Published: May 10, 2026

Transformation of ALK-translocated lung adenocarcinoma to LCNEC under alectinib treatment - a case report and mini-review.

Transformation of ALK-translocated lung adenocarcinoma to LCNEC under alectinib treatment - a case report and mini-review.

Journal: The oncologist
Published: April 27, 2026

Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in Italy.

Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in Italy.

Journal: Journal of medical economics
Published: April 27, 2026
Showing 1-12 of 1,425

Last Updated: 06/30/2026